17-Apr-2024
No headlines found.
Globe Newswire (Sun, 7-Apr 2:45 PM ET)
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Globe Newswire (Mon, 1-Apr 8:00 AM ET)
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 26-Mar 8:00 AM ET)
Globe Newswire (Mon, 25-Mar 4:00 PM ET)
Business Wire (Fri, 22-Mar 6:26 PM ET)
Globe Newswire (Fri, 22-Mar 3:10 PM ET)
Globe Newswire (Fri, 22-Mar 11:04 AM ET)
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 27-Feb 6:00 AM ET)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Feb 4:30 PM ET)
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
Globe Newswire (Tue, 13-Feb 8:00 AM ET)
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Esperion Therapeutics trades on the NASDAQ stock market under the symbol ESPR.
As of April 17, 2024, ESPR stock price declined to $1.84 with 3,585,146 million shares trading.
ESPR has a beta of 4.35, meaning it tends to be more sensitive to market movements. ESPR has a correlation of 0.21 to the broad based SPY ETF.
ESPR has a market cap of $340.50 million. This is considered a Small Cap stock.
Last quarter Esperion Therapeutics reported $32 million in Revenue and -$.50 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.02.
In the last 3 years, ESPR stock traded as high as $28.78 and as low as $.70.
The top ETF exchange traded funds that ESPR belongs to (by Net Assets): VTI, VXF, IWC, JFWD, AVUS.
ESPR has outperformed the market in the last year with a return of +47.2%, while the SPY ETF gained +23.0%. However, in the most recent history, ESPR shares have underperformed the stock market with its stock returning -34.5% in the last 3 month period and -36.1% for the last 2 week period, while SPY has returned +5.7% and -3.5%, respectively.
ESPR support price is $1.77 and resistance is $2.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ESPR stock will trade within this expected range on the day.